Literature DB >> 34021620

Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease.

Sebastian Heinzel1, Velma T E Aho2,3, Ulrike Suenkel4, Anna-Katharina von Thaler4, Claudia Schulte4,5, Christian Deuschle4,5, Lars Paulin2, Sari Hantunen6, Kathrin Brockmann4,5, Gerhard W Eschweiler7,8, Walter Maetzler1, Daniela Berg1,4, Petri Auvinen2, Filip Scheperjans3.   

Abstract

OBJECTIVE: Alterations of the gut microbiome in Parkinson disease (PD) have been repeatedly demonstrated. However, little is known about whether such alterations precede disease onset and how they relate to risk and prodromal markers of PD. We investigated associations of these features with gut microbiome composition.
METHODS: Established risk and prodromal markers of PD as well as factors related to diet/lifestyle, bowel function, and medication were studied in relation to bacterial α-/β-diversity, enterotypes, and differential abundance in stool samples of 666 elderly TREND (Tübingen Evaluation of Risk Factors for Early Detection of Neurodegeneration) study participants.
RESULTS: Among risk and prodromal markers, physical inactivity, occupational solvent exposure, and constipation showed associations with α-diversity. Physical inactivity, sex, constipation, possible rapid eye movement sleep behavior disorder (RBD), and smoking were associated with β-diversity. Subthreshold parkinsonism and physical inactivity showed an interaction effect. Among other factors, age and urate-lowering medication were associated with α- and β-diversity. Constipation was highest in individuals with the Firmicutes-enriched enterotype, and physical inactivity was most frequent in the Bacteroides-enriched enterotype. Constipation was lowest and subthreshold parkinsonism least frequent in individuals with the Prevotella-enriched enterotype. Differentially abundant taxa were linked to constipation, physical inactivity, possible RBD, smoking, and subthreshold parkinsonism. Substantia nigra hyperechogenicity, olfactory loss, depression, orthostatic hypotension, urinary/erectile dysfunction, PD family history, and the prodromal PD probability showed no significant microbiome associations.
INTERPRETATION: Several risk and prodromal markers of PD are associated with gut microbiome composition. However, the impact of the gut microbiome on PD risk and potential microbiome-dependent subtypes in the prodrome of PD need further investigation based on prospective clinical and (multi)omics data in incident PD cases. ANN NEUROL 2021.
© 2021 American Neurological Association.

Entities:  

Year:  2021        PMID: 34021620     DOI: 10.1002/ana.26128

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  Clinical Features in Parkinson's Disease Patients with Hyperechogenicity in Substantia Nigra: A Cross-Sectional Study.

Authors:  Sha Zhu; Yaxi Wang; Yinyin Jiang; Ruxin Gu; Min Zhong; Xu Jiang; Bo Shen; Jun Zhu; Jun Yan; Yang Pan; Li Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-02       Impact factor: 2.989

Review 2.  Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies.

Authors:  Miriam Højholt Terkelsen; Ida H Klaestrup; Victor Hvingelby; Johanne Lauritsen; Nicola Pavese; Marina Romero-Ramos
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies.

Authors:  Michal Lubomski; Xiangnan Xu; Andrew J Holmes; Samuel Muller; Jean Y H Yang; Ryan L Davis; Carolyn M Sue
Journal:  Front Aging Neurosci       Date:  2022-05-17       Impact factor: 5.702

Review 4.  Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses.

Authors:  Honglei Chen; Keran Wang; Filip Scheperjans; Bryan Killinger
Journal:  Neurobiol Dis       Date:  2021-12-23       Impact factor: 7.046

Review 5.  Gut-Derived Sterile Inflammation and Parkinson's Disease.

Authors:  Kathleen M Shannon
Journal:  Front Neurol       Date:  2022-03-29       Impact factor: 4.003

Review 6.  Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease.

Authors:  Manlian Zhu; Xia Liu; Yiru Ye; Xiumei Yan; Yiwen Cheng; Longyou Zhao; Feng Chen; Zongxin Ling
Journal:  Front Immunol       Date:  2022-06-24       Impact factor: 8.786

7.  Fecal microbiome alterations in treatment-naive de novo Parkinson's disease.

Authors:  Jeffrey M Boertien; Kirsi Murtomäki; Pedro A B Pereira; Sygrid van der Zee; Tuomas H Mertsalmi; Reeta Levo; Tanja Nojonen; Elina Mäkinen; Elina Jaakkola; Pia Laine; Lars Paulin; Eero Pekkonen; Valtteri Kaasinen; Petri Auvinen; Filip Scheperjans; Teus van Laar
Journal:  NPJ Parkinsons Dis       Date:  2022-10-10

8.  Inflammatory gut as a pathologic and therapeutic target in Parkinson's disease.

Authors:  Jea-Young Lee; Zhen-Jie Wang; Alexa Moscatello; Chase Kingsbury; Blaise Cozene; Jeffrey Farooq; Madeline Saft; Nadia Sadanandan; Bella Gonzales-Portillo; Henry Zhang; Felipe Esparza Salazar; Alma Rosa Lezama Toledo; Germán Rivera Monroy; Reed Berlet; Cyndy D Sanberg; Paul R Sanberg; Cesario V Borlongan
Journal:  Cell Death Discov       Date:  2022-09-24

Review 9.  The Gut-Brain Axis and Its Relation to Parkinson's Disease: A Review.

Authors:  Emily M Klann; Upuli Dissanayake; Anjela Gurrala; Matthew Farrer; Aparna Wagle Shukla; Adolfo Ramirez-Zamora; Volker Mai; Vinata Vedam-Mai
Journal:  Front Aging Neurosci       Date:  2022-01-07       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.